| Filings | Filing Date | Form Type | Company | Description | AI | Link |
|---|---|---|---|---|---|---|
| Filings | Description | AI | Link | |||
|---|---|---|---|---|---|---|
BERKSHIRE HATHAWAY ENERGY CO 7.01Reg FD9.01Exhibits | Nov 9, 20267:53 AM ET | 8-K | BERKSHIRE HATHAWAY ENERGY CO | 7.01Reg FD9.01Exhibits Berkshire Hathaway Energy filed an 8-K under Item 7.01 on November 9, 2026, disclosing that it posted its 'EEI Financial Conference November 2026' investor materials on its website… | ||
 BCAXBicara Therapeutics Inc. 2.02Results of operations9.01ExhibitsExhibits:EX-99.1 | Nov 9, 20267:52 AM ET | 8-K | BCAX Bicara Therapeutics Inc. | 2.02Results of operations9.01ExhibitsExhibits:EX-99.1 | ||
 RDNTRadNet, Inc. 2.02Results of operations9.01ExhibitsExhibits:EX-99.1 | Nov 9, 20267:50 AM ET | 8-K | RDNT RadNet, Inc. | 2.02Results of operations9.01ExhibitsExhibits:EX-99.1 | ||
 CRMDCorMedix Inc. 1.01Material agreement2.03Direct financial obligation3.02Unregistered sale+2Exhibits:EX-10.1EX-10.2+4 | Nov 9, 20267:49 AM ET | 8-K | CRMD CorMedix Inc. | 1.01Material agreement2.03Direct financial obligation3.02Unregistered sale+2Exhibits:EX-10.1EX-10.2+4 | ||
 SPRCSciSparc Ltd. Exhibits:EX-4.1EX-4.2 | Nov 9, 20267:48 AM ET | 6-K/A | SPRC SciSparc Ltd. | Exhibits:EX-4.1EX-4.2 SciSparc filed this 6-K/A on November 9, 2026 solely to correct a typographical error in the Floor Price of the $3,000,000 Convertible Promissory Note issued to L.I.A. Pure Capital… | ||
 DAVIDAVION HEALTHCARE PLC Exhibits:EX-99.1 | Nov 9, 20267:46 AM ET | 6-K | DAVI DAVION HEALTHCARE PLC | Exhibits:EX-99.1 | ||
 AIRIAIR INDUSTRIES GROUP 2.02Results of operations9.01ExhibitsExhibits:EX-99.1 | Nov 9, 20267:43 AM ET | 8-K | AIRI AIR INDUSTRIES GROUP | 2.02Results of operations9.01ExhibitsExhibits:EX-99.1 | ||
 HRTXHERON THERAPEUTICS, INC. /DE/ 1.01Material agreement3.03Rights of holders modified7.01Reg FD+1Exhibits:EX-10.1EX-10.2+5 | Nov 9, 20267:40 AM ET | 8-K | HRTX HERON THERAPEUTICS, INC. /DE/ | 1.01Material agreement3.03Rights of holders modified7.01Reg FD+1Exhibits:EX-10.1EX-10.2+5 | ||
 BPOPPOPULAR, INC. 8.01Other events9.01Exhibits | Nov 9, 20267:39 AM ET | 8-K | BPOP POPULAR, INC. | 8.01Other events9.01Exhibits Popular, Inc. filed an 8-K disclosing that a quick service restaurant borrower of Banco Popular de Puerto Rico substantially ceased operations and filed for Chapter 11 bankruptcy a… | ||
 IBRXImmunityBio, Inc. 2.02Results of operations9.01ExhibitsExhibits:EX-99.1 | Nov 9, 20267:39 AM ET | 8-K | IBRX ImmunityBio, Inc. | 2.02Results of operations9.01ExhibitsExhibits:EX-99.1 | ||
 VRDNViridian Therapeutics, Inc.\DE 7.01Reg FD8.01Other events9.01ExhibitsExhibits:EX-99.1 | Nov 9, 20267:33 AM ET | 8-K | VRDN Viridian Therapeutics, Inc.\DE | 7.01Reg FD8.01Other events9.01ExhibitsExhibits:EX-99.1 Viridian Therapeutics announced positive phase 1 results for VRDN-008, a half-life extended bispecific FcRn inhibitor, showing 74% peak IgG reduction and a 15-18 day half-life in h… | ||
 GTGOODYEAR TIRE & RUBBER CO /OH/ 5.02Officer/director change7.01Reg FD9.01ExhibitsExhibits:EX-99.1 | Nov 9, 20267:32 AM ET | 8-K | GT GOODYEAR TIRE & RUBBER CO /OH/ | 5.02Officer/director change7.01Reg FD9.01ExhibitsExhibits:EX-99.1 | ||
 ANTXAN2 Therapeutics, Inc. 2.02Results of operations9.01ExhibitsExhibits:EX-99.1 | Nov 9, 20267:31 AM ET | 8-K | ANTX AN2 Therapeutics, Inc. | 2.02Results of operations9.01ExhibitsExhibits:EX-99.1 | ||
 SLNHSoluna Holdings, Inc 7.01Reg FD9.01ExhibitsExhibits:EX-99.1 | Nov 9, 20267:30 AM ET | 8-K | SLNH Soluna Holdings, Inc | 7.01Reg FD9.01ExhibitsExhibits:EX-99.1 Soluna Holdings announced it will release its third quarter 2026 financial results on Monday, November 16, 2026, followed by a conference call and webcast at 5:00 PM ET. The filing… | ||
 NCPLNetcapital Inc. 3.01Delisting notice9.01ExhibitsExhibits:EX-99.1 | Nov 9, 20267:30 AM ET | 8-K | NCPL Netcapital Inc. | 3.01Delisting notice9.01ExhibitsExhibits:EX-99.1 | ||
 AZRAzora Therapeutics, Inc. 5.02Officer/director change8.01Other events9.01Exhibits | Nov 9, 20267:30 AM ET | 8-K | AZR Azora Therapeutics, Inc. | 5.02Officer/director change8.01Other events9.01Exhibits | ||
 INOINOVIO PHARMACEUTICALS, INC. 1.01Material agreement7.01Reg FD8.01Other events+1Exhibits:EX-1.1EX-4.1+3 | Nov 9, 20267:30 AM ET | 8-K | INO INOVIO PHARMACEUTICALS, INC. | 1.01Material agreement7.01Reg FD8.01Other events+1Exhibits:EX-1.1EX-4.1+3 | ||
 AVIRAtea Pharmaceuticals, Inc. 1.01Material agreement2.03Direct financial obligation9.01ExhibitsExhibits:EX-10.1 | Nov 9, 20267:30 AM ET | 8-K | AVIR Atea Pharmaceuticals, Inc. | 1.01Material agreement2.03Direct financial obligation9.01ExhibitsExhibits:EX-10.1 | ||
 OCULOCULAR THERAPEUTIX, INC 5.02Officer/director change | Nov 9, 20267:28 AM ET | 8-K | OCUL OCULAR THERAPEUTIX, INC | 5.02Officer/director change | ||
 SLXNSilexion Therapeutics Corp 8.01Other events9.01ExhibitsExhibits:EX-99.1 | Nov 9, 20267:26 AM ET | 8-K | SLXN Silexion Therapeutics Corp | 8.01Other events9.01ExhibitsExhibits:EX-99.1 Silexion Therapeutics (NASDAQ: SLXN) announced a 1-for-24 reverse share split, effective after market close on November 10, 2026, with split-adjusted trading beginning at market op… |
Searching Signal8’s SEC filing archive — filings from Oct 2021 onward.
1-20 of 10,000+ filings